Fortnightly review: Update on male erectile dysfunction

British Medical Journal

Volumn 316, Issue 7132, 1998, Pages 678-682

  Wagner, G ^a,b   Saenz De Tejada, I ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b International Ruber Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; APOMORPHINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DIGOXIN; HORMONE; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; PROSTAGLANDIN E1; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; YOHIMBINE;

ALCOHOLISM; ANATOMY; DEVICE; GASTROINTESTINAL SYMPTOM; HUMAN; IMPOTENCE; MALE; PATIENT COUNSELING; PENIS ERECTION; PHYSIOLOGY; PRIORITY JOURNAL; PROSTHESIS; REVIEW; SOMNOLENCE; HISTOLOGY; PENIS; PENIS PROSTHESIS;

HUMANS; IMPOTENCE; MALE; PENILE ERECTION; PENILE PROSTHESIS; PENIS;

EID: 0032573913     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.316.7132.678     Document Type: Review

References (41)

1. Korenman SG. Advanced in the understanding and management of erectile dysfunctioan. J Clin Endocrinol Metab 1995;60:1985-8.
2. Krane RJ. Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989;321:1648-9.
3. Feldman HA. Goldstein I, Hatzichristou DG, Krane RJ. McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massuchusetts male ageing study J Urol 1994;151:54-61.
4. Zemel P. Sexual dysfunction in the diabetic patient with hypertension. Am J Cardiol 1988;61:27-33H.
5. Rubin A. Babbot D. Impotence and diabetes mellitus JAMA 1958; 168:498.
6. Andersson K-E, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
7. Christ GJ. The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Urol Clin N Am 1995;22:727-45.
8. De Groat WC, Booth AM. Neural control of penile erection. In: Maggi CA, ed. The autonomic nervous system. Nervous control of the urogenital system. Vol. 6. London: Harwood, 1993:465-513.
9. Butnett AL, Role of nitrie oxide in the physiology of erection. Biol Reprod 1995;52:485-9.
10. Palmer RMJ. Fettige AJ, Moncada S. Nitrie oxide accounts for the biological activitiy of endothelium-derived relaxing factor. Nature 1987;327:524-6.
11. Ignarro I.J, Bush PA. Buga GM, Wood KS, Fukoto JM. Rajfer J. Nitrie oxide and cvclic GMP formation upon electrical field Stinulation cause relaxation of corpus cavernosurn smooth muscle. Biochem Biophys Rev Connmun 1990;170:843-50.
12. Burnett AL, Hillman SL, Chang. TSK. Epstein JI. Lowenstein CJ, Bredt DS. et al Inimunohistochemical localisation of nitrie oxide synthase in the autonomic the innervation of the human penis. J Urol 1993;150:73-6.
13. Saenz de Tejada I, Blanco R, Goldstein I. Azadzoi K, de las Morenas A, Krane RJ, et al. Cholinergic neurotransmission in human corpus cavernosum. I. Responses of isolated tissue, Am J Physiol 1988;254:11459-67.
14. Carrier S, Zvar P, Lue TF Erectile dysfunction, Endocrinol Metab clin N Am 1994;23:773-82.
15. Greenstein A. Plymate SR, Katz PG. Visually stimulated eretion in castrated men. J Urol 1995;153:650-2.
16. Kirby RS, Impotence: diagnosis and management of male erectile dyfunction BMJ 1994;308:957-61.
17. O'Keete, M. Hunt DK, Assessment and treatment of impotence, Med Clin N Am 1995;79:415-34.
18. Bullum J Pharmacosexuology update: prescription drugs and sexual function. J Psychoactive Drugs 1986;18:97-106.
19. TOMHS research group, Incidence and disappearance of erectile problems in men treated for stage I hypertesion: the treatment of mild hypertension study (TOMHS), Eur Urol 1996;30(suppl 2):38.
20. Balon R, Yeragaui VK. Pohl R. Ramesh C. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993;54:209-12.
21. Guay AT. Erectile dystunction are you prepared to discuss it? Postgrad Med 1995;97:127-43.
22. Wagner G, Jensen SB, Alcohol and erectile, failure. In: Wagner G. Green R. eds Impotence, physiological, psycholoical, surgical diagnosis and treatment. New York: Plenum, 1981.
23. Lue TF. Impotence: a patient's goal-directed approach to treatment. World J Urol 1990;8:67-74.
24. Li MK, Lau KO. Clinical cvaluation of impotence. Am Acad Med 1995;24:741-4.
25. Lewis RW, Mayda J II. Diagnosis and treatment of vasculogenie impotence. Acta Chir Hung 1994;34:231-44.
26. Kurt U, Ozkarde SH, Altug E, Geriniyanoglu C. Gurdal M, Erol D. The elficacy of anti-seiotonergic agents in the treatment of erectile dysfunction. J Urol 1991:152:407-9.
27. Meinhardt W, Kropman RF, de la Fuerte RF. Lycklama A. Nijeholt GAB. Zwartendijk J Oral treatment of impotence, trazodone versus placebo [abstract]. Int J Impotence Res 1996;8:116.
28. Morales A, Heaton JPW, Johnston B, Adams M, Oral and topical treatment of erectile dysfunction present and future. Urol Clin N Am 1995;165:60-3.
29. Reid K, Surridge DHC. Morales A. Condra M. Harris C. Owen J, et al, Double-blind trial of yohimbine in the treatment of psychogenic impotence, Lancet 1987;ii:421-3.
30. Boolell M, Gepi-Anee S. Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257-61.
31. Gingell C. Jardin A, Giuliano FA. Olsson AM. Dinstnore WW ,Osterloh IH, et al. The efficacy of sildenafil (Viagra), a new oral treatment for erectile dysfunction, demonstrated by four different methods in a double-blind placeho-controllld, multiational clincal trial [abstraet]. Eur Urol 1996;30(suppl 2):353.
32. Eardley I, Morgan R, Dinsmore W, Pearson J, Wulff M, Boolell M. Evaluation of the elficacy of sildenafil (Pftzer UK-92,180) a new oral treatment for male erectile dystuntion (MKD) in a double-blind, placebo controlled study [abstract].Eur Urol 1996;30(suppl 2):355.
33. Buvat JS, Gingell GJ, Jardin, A, Olsson AM. Dinsmore WW. Kirkpatrick J, et al. Sildenalil (Viagra), an oral treatment for erectile dysfunction: a 1-year open-label, extension study. J Urol 1997;157(suppl):204.
34. Derry F,Gardner BP, Glass C, Farser M, Dinsmore WW, Muirhead G, et al. Sildenafil (Viagra): a double-blind, placebo-controlled, single dose, two-way cross-over study in men with erectile dyslunction caused by traumatic spinal cord injury. J Urol 1997;157(suppl):181.
35. Lue TF, Sildenafil Study Group. A study of sildenatil (Viagra), a new oral agent for the treatment of male eretile dysfucntion. J Urol 1997;157(suppl):181.
36. Derry F, Glass C.Dinsmore WW, Fraset M, Garduer BP, Mayton M, et al. Sildenafil (Viagra): an oral treatment for men with erectile dysfunction caused by traumatic spinal cord injury a 28-day. double-blind, placebocontrolled, parallel-group dose-respones study [abstract]. Neurology 1997;48(suppl 2):215.
37. Boolell M, Pearson J, Gingell; JC, Gepi-Attee S, Wareham K. Price D. Sildenafil (Viagra) is an elfrcacious oral therapy in diabetic patients with eretile dysfunction. Int J Impot Rev 1996;8:186.
38. Boolell M, Allen MJ, Ballard SA. Gepi-Attee S, Muirhead GJ, Naytor AM, et al. An orally active type 5 eyelie GMP-specific phosphodiesrerase inhibitor for the treatment of penile eretile dysfunction, Int. J Impotence Res 1996;8:17-52.
39. Heaton JPW, Morales A, Adams MA, Johnsion B, Recovery of erectile function by the oral administration of apomorphine, Urology 1995;45:200-6.
40. Wagner G, Lacy S, Lewis R. Buccal phentolamine, A pilot trial for male erectile dysfunction at three separate dinies. Int J Impotence Res 1994;6(suppl 1):D78.
41. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with tansurethral alprostadil, Medicated urethral system for erection (MUSE) study group. N Engl J Med 1997;336:1-7.